Skip to content
Life Sciences Series B Founded 2016

JUMPCODE Genomics

JumpCode provides technology for depleting unwanted nucleic acid. The CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to deplete unwanted nucleic acid molecules from sequencing libraries. The applications of the technology include host organism depletion, ribosomal RNA depletion, repetitive sequence depletion, allele-specific depletion, and others. The patented CRISPRclean technology…

📍 Carlsbad, United States · Genomics,

Funding snapshot

Last roundSeries B
Amount$384K
Date24 February 2025
Total raised$39M
Team size7

About

JumpCode provides technology for depleting unwanted nucleic acid. The CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to deplete unwanted nucleic acid molecules from sequencing libraries. The applications of the technology include host organism depletion, ribosomal RNA depletion, repetitive sequence depletion, allele-specific depletion, and others. The patented CRISPRclean technology allows the researcher to remove unwanted regions. The company was founded in 2016 and headquartered in Carlsbad, United States. It has raised $38.7M in series b funding, with backing from Baird Capital, Arboretum Ventures, LYZZ Capital, HHS. The company operates in the Life Sciences - Genomics, Life Sciences - Life Sciences Platforms and Tools, HealthTech - Life Sciences Tech space. Provider of a technology for depleting unwanted nucleic acid.

Business model

Life Sciences Tech > Research & Development > Drug Informatics > Scientific Literature > Data Mining > Gene Analysis,

Genomics > Enabling Technologies > Kits and Reagents > Detection and Quantification,

Life Sciences Platforms and Tools > Research Reagents and Kits > Genomics > Nucleic Acid Synthesis > DNA

Institutional investors

Baird Capital Arboretum Ventures LYZZ Capital HHS

Latest coverage

No articles yet.

Raising like JUMPCODE Genomics?

Analyze your pitch deck before your next raise.

Analyze My Deck →